

09/918, 500

=> d his

(FILE 'HOME' ENTERED AT 08:56:38 ON 06 SEP 2004)

FILE 'BIOSIS, MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 08:57:33 ON 06 SEP 2004

L1 109 S SUBTRATE AND WELLS
L2 0 S L1 AND FIBER (5A) WELLS
L3 1 S L1 AND FIBER (10A) WELL?
L4 0 S L1 AND NYLON? (4A) WELL?
L5 2 S L1 AND NYLON? (10A) WELL?
L6 2 S L1 AND CELLULOSE? (10A) WELL?

=> d l3 bib abs

L3 ANSWER 1 OF 1 USPATFULL on STN
AN 2003:237481 USPATFULL
TI Inorganic fiber substrates for exhaust systems and methods of making same
IN Louks, John W., North Hudson, WI, UNITED STATES
Wood, Thomas E., Stillwater, MN, UNITED STATES
Tan, Zhongshu, St. Paul, MN, UNITED STATES
Yorkgitis, Elaine M., St. Paul, MN, UNITED STATES
Femrite, Timothy J., Hugo, MN, UNITED STATES
Schornak, Elizabeth M., St. Paul, MN, UNITED STATES
Munoz, Juan A., Blaine, MN, UNITED STATES
Werner, Paul S., Woodbury, MN, UNITED STATES
PI US 2003165638 A1 20030904
AI US 2003-339683 A1 20030108 (10)
RLI Continuation-in-part of Ser. No. WO 2002-US21333, filed on 3 Jul 2002, PENDING
PRAI US 2001-303563P 20010706 (60)
DT Utility
FS APPLICATION
LREP 3M INNOVATIVE PROPERTIES COMPANY, PO BOX 33427, ST. PAUL, MN, 55133-3427
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 3322
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for rigidifying a fiber-based paper substrate for use in the exhaust system of a combustion device. In the method, a green ceramic fiber-based paper substrate is impregnated with an impregnating material. The impregnated substrate is fired to form a rigidified substrate that is suitable for use in the exhaust system of a combustion device. This rigidification process is performed at least once and, preferably, two or more times.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l5 bib abs 1-2

L5 ANSWER 1 OF 2 USPATFULL on STN
AN 2001:142130 USPATFULL
TI Sialyltransferases
IN Kapitonov, Dmitri, 1327 Spruce St., Apt. 5E, Philadelphia, PA, United States 19107
Yu, Robert K., 306 Cheswick, Richmond, VA, United States 23229
PI US 6280989 B1 20010828
AI US 1999-334601 19990617 (9)
DT Utility
FS GRANTED

EXNAM Primary Examiner: Patterson, Jr., Charles L.
LREP Millen White Zelano & Branigan
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 2057

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to isolated sialyltransferases, such as human or mouse GM3 synthase, human or mouse 4ST3GalVI, or human 7STGalNAcV sialyltransferase polypeptide, biologically-active polypeptide fragments thereof, and nucleic acids which code for it. This polypeptide has various activities including sialyltransferase activity. The invention relates to all aspects of sialyltransferase, or homologs thereof, including assays for modulators, activators, ligands, etc. The invention also relates to sialyltransferases expressed in cells and methods of using such cells to engineer specific sugar chains.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 2 USPATFULL on STN
AN 89:80723 USPATFULL
TI Immobilized biotinylated receptor in test device, kit and method for determining a ligand
IN Smith-Lewis, Margaret J., Pittsford, NY, United States
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)
PI US 4870007 19890926
AI US 1987-136211 19871218 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Tucker, J. Lanny
CLMN Number of Claims: 22
ECL Exemplary Claim: 1,8
DRWN No Drawings
LN.CNT 754

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A device useful for the determination of a ligand in an aqueous liquid comprises a water-insoluble substrate. Immobilized in at least one location on that substrate is a biotinylated receptor for the ligand. This receptor is in dried form and immobilized with one or more dried water-soluble acrylamide homo- or copolymer binder materials. When the immobilized receptor is contacted with an aqueous sample, the binder material is dissolved and the receptor is released for reaction with the ligand. The resulting reaction product is determined in a suitable manner. The device can be included in a kit having other components useful for ligand determination. The device and method of its use are particularly useful for the determination of human chorionic gonadotropin (hCG) as an early indicator of pregnancy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 16 bib abs 1-2

L6 ANSWER 1 OF 2 USPATFULL on STN
AN 2003:319505 USPATFULL
TI Tumour necrosis factor binding ligands
IN Rathjen, Deborah Ann, Flagstaff Hill, AUSTRALIA
Aston, Roger, South Carney, UNITED KINGDOM
PI US 2003225254 A1 20031204
AI US 2003-359934 A1 20030207 (10)
RLI Continuation of Ser. No. US 2002-327541, filed on 20 Dec 2002, PENDING
Continuation of Ser. No. US 2002-265451, filed on 3 Oct 2002, PENDING
Continuation of Ser. No. US 2000-736630, filed on 13 Dec 2000, GRANTED,

Pat. No. US 6593458 Continuation of Ser. No. US 1999-364039, filed on 30 Jul 1999, GRANTED, Pat. No. US 6416757 Continuation of Ser. No. US 1997-823893, filed on 17 Mar 1997, GRANTED, Pat. No. US 5959087 Continuation of Ser. No. US 1994-344133, filed on 23 Nov 1994, GRANTED, Pat. No. US 5644034 Continuation-in-part of Ser. No. US 1992-828956, filed on 18 Feb 1992, ABANDONED A 371 of International Ser. No. WO 1990-AU337, filed on 7 Aug 1990, UNKNOWN

PRAI AU 1989-5662 19890807
AU 1989-7576 19891124

DT Utility

FS APPLICATION

LREP MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018

CLMN Number of Claims: 8

ECL Exemplary Claim: 1

DRWN 28 Drawing Page(s)

LN.CNT 1457

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABS) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPATFULL on STN

AN 2003:185551 USPATFULL

TI Integrated solid-phase hydrophilic matrix circuits and micro-arrays

IN Lauks, Imants, Ottawa, CANADA

Pierce, Raymond J., Ottawa, CANADA

Wojtyk, James, Ottawa, CANADA

Bergevin, Benoit R., Vankleek Hill, CANADA

PI US 2003127333 A1 20030710

AI US 2002-307468 A1 20021202 (10)

RLI Continuation-in-part of Ser. No. US 2001-871821, filed on 4 Jun 2001, PENDING

DT Utility

FS APPLICATION

LREP BORDEN LADNER GERVAIS LLP, WORLD EXCHANGE PLAZA, 100 QUEEN STREET SUITE 1100, OTTAWA, ON, K1P 1J9

CLMN Number of Claims: 56

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 3209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to analytical devices and micro-arrays with integral fluidic inputs and outputs. The devices are constructed from planar solid-phase hydrophilic matrix circuits containing dry chemical reagents overlaying integral electro-kinetic pumping electrodes. The hydrophilic matrix circuits are enclosed within a gas permeable electrical insulator. The devices are for use in micro-scale bio-analysis, mixture separation and reaction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.